A Phase 2 interventional study of Vidutolimod (CMP-001) and Nivolumab in Melanoma, sponsored by Diwakar Davar. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-02.
Sponsored by Diwakar Davar · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 142 studies testing nivolumab in Melanoma — 32 open to participants now, 62 under way, 9 of them phase 3. Nivolumab · Melanoma.
Among the 142 studies testing nivolumab in Melanoma, this one is the 115th largest by enrollment, is one of 12 that started in 2020, is one of 76 in phase 2, and was the 81st registered.
3,374 studies on the registry are indexed under Melanoma; 581 are open to participants now.
Browse Melanoma studies →32 of the 142 studies testing nivolumab in Melanoma are open now, in 12 countries. Recruiting first, the newest first:
University of Wisconsin, Madison · Sites in United States
Ages 18+
Swiss Cancer Institute · Sites in Switzerland
Ages 18+
Melanoma and Skin Cancer Trials Limited · Sites in Australia
Ages 18+
Radboud University Medical Center · Sites in Netherlands
Ages 18+
UNC Lineberger Comprehensive Cancer Center · Sites in United States
Ages 18+
By country, each count listing its studies:
Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 468 Melanoma studies recruiting now, 381 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, nivolumab is the treatment under test here. Read study by study →
142 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 39 · Phase 2 94 · Phase 3 20 · Phase 4 4
First in 2006; this study’s year is marked. 12 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 9 is below the median of 40 across 2,652 interventional studies indexed under Melanoma.
Median enrollment 50 across the 142 interventional studies. Of the 63 that completed or were terminated, 35 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 142 have an industry lead sponsor. The 10 most frequent:
Diwakar Davar is the lead sponsor of 13 studies on the registry; 3 are open to participants now.
Diwakar Davar has 9 studies filed under Melanoma — fewer than ten, so there is no comparison to draw.
13 of the studies testing nivolumab in Melanoma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04309409Phase 3University Hospital, EssenAdjuvant Nivolumab Treatment in Stage II (IIA, IIB, IIC) High-risk Melanoma | 2027-09 |
| NCT06712927Stanford UniversityTrial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain Metastases | 2026-11 |
| NCT07155317Emory UniversityTime-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial | 2026-12-31 |
| NCT03685890Vastra Gotaland RegionEvaluating the Effect of Nivolumab for Patients With In-transit Metastases Treated With Isolated Limb Perfusion | 2026-12-31 |
| NCT05136196National Cancer Institute (NCI)BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study | 2027-01-01 |
Add all 13 to your calendar (.ics) → With an account.
Among the 142 studies testing nivolumab in Melanoma, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main goal of this research study is to determine how nivolumab and nivolumab/Vidutolimod (CMP-001) combination affect the likelihood of destroying melanoma involving lymph node and/or in-transit/satellite areas.
The main goal of the PET/CT scan with 18F]F-AraG is to evaluate how [18F]F-AraG uptake changes before and after administration of either nivolumab or nivolumab/CMP-001 combination.
This is a phase II pilot study designed to compare the pCR rate of two neoadjuvant immunotherapies in high-risk resectable melanoma with two integrated biomarkers. The integrated [18F]F-AraG imaging biomarker images activated CD8+ T cells. The CD8+ T cell density biomarker quantitates CD8+ T Cells using an automated method. The primary purpose of the study is to describe the correlation between pCR and the distribution of either biomarkers in patients receiving either neoadjuvant Vidutolimod (CMP-001)/nivolumab or neoadjuvant nivolumab.
Patients with stage IIIB-IIID cutaneous (or unknown primary) melanoma with palpable nodal disease who have yet to undergo definitive surgery are eligible to enroll. Patients with nodal relapse including those who have received prior adjuvant IFN and/or ipilimumab are eligible to enroll.
Suitable patients will be identified pre-operatively. Patients will undergo a 28 day screening evaluation including surgical assessment, clinical assessment, systemic/CNS staging scans, and laboratory studies to confirm suitability. Patients will undergo biopsies of both planned injected and uninjected lesions (Arm A) and target lesion (Arm B). Biopsies of these lesions will occur pre-treatment, at W3 or W4 and the target lesion(s) will be resected at the time of surgery.
Eligible patients will be randomized 1:1 to receive Arm A (neoadjuvant Nivolumab/(CMP) vs. Arm B (neoadjuvant Nivolumab) during the (Prime Phase) pre-operatively. Patients randomized to Arm A will receive: Nivolumab 240mg IV q2 x3 and CMP-001 5mg SC 1st dose then 10mg IT 2nd-7th doses (7 weeks). Patients randomized to Arm B will receive: Nivolumab 240mg IV q2 x3 (6 weeks).
[18F]F-AraG PET-CT scan (18-F PET) is an integrated biomarker and will be performed at 2 imaging time-points: pre-treatment (pre-W1) and on-treatment (W2). At each imaging timepoint, [18F]F-AraG will be administered by a licensed nuclear medicine technologist under the supervision of a nuclear medicine physician on an outpatient basis. Each patient will receive a single bolus injection of 5 mCi [18F]F-AraG IV into a hand or arm vein. At Screening and W2 imaging timepoints, following [18F]F-AraG injection, a 30-min static PET-CT scan will be performed covering the brain to the upper legs.
For CD8+ T cell density assessments, patients will undergo biopsies at 2 timepoints: pre-treatment (Screening) and on-treatment (W3 or W4). In Arm A, patients will undergo biopsies of planned injected and a 2nd uninjected lesion. At each imaging timepoint, biopsies will be performed.
Following the Prime Phase and restaging systemic scans, patients will undergo surgical resection.
Post-operatively, patients will continue to receive maintenance therapy (Boost Phase) per randomization. In the Boost Phase, patients randomized to Arm A (neoadjuvant Nivolumab/(CMP) will receive 480mg IV q4 x12 along with Vidutolimod (CMP-001) 5mg SC q4 x12 over a 48 week period; while patients randomized to Arm B (neoadjuvant Nivolumab) will receive Nivolumab (480mg IV q4 x12 over a 48 week period). In the post-operative period, CMP-001 will be administered subcutaneously (Arm A only).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosis of or cytologically confirmed diagnosis of cutaneous melanoma belonging to one of the following AJCC TNM stages:
Patients are eligible for this trial either at presentation for primary melanoma with concurrent regional nodal ; or at the time of clinical detected nodal recurrence; and may belong to any of the following groups:
Demonstrate adequate organ function as defined below performed on screening labs obtained within 4 weeks of registration.
Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject.
Exclusion Criteria:
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1 or who has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to a previously administered agent.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Prime Phase - Nivolumab 240mg IV, every 2 weeks starting with Cycle 2 (Cycles 2,4,6) for 6 weeks in combination with Vidutolimod 5mg subcutaneous 1st dose, and the remaining injections, 10mg intra-tumorally will be administered Weeks 2-7. \[18F\]F-AraG PET/CT, single bolus injection of 5 (±10%) mCi IV into a vein, Screening and at Week 2. Boost Phase - Nivolumab 480mg IV, every 4 weeks and CMP-001 5mg subcutaneous every 4 weeks up to 48 weeks.
Drug: Vidutolimod (CMP-001) · Biological: Nivolumab · Other: [18F]F-AraG PET/CT
Prime Phase - Nivolumab 240mg IV, every 2 weeks starting with Cycle 2 (Cycles 2, 4, 6) for 6 weeks. \[18F\]F-AraG PET/CT, single bolus injection of 5 (±10%) mCi IV into a vein, Screening and at Week 3. Boost Phase - Nivolumab 480mg IV, every 4 weeks starting from the time of surgery recovery for up to 48 weeks.
Biological: Nivolumab · Other: [18F]F-AraG PET/CT
A molecule comprised of a 30 nucleotide strand, flanked by 10 guanines on either end. The nucleotide strand is surrounded by a Qβ viral-like protein. The intended mechanism of action of CMP-001 in oncology is the activation of TLR9 in pDC within the tumor or the tumor-draining lymph nodes (tumor-associated pDC).
a fully human Ig G4 antibody that blocks PD-1. Nivolumab was initially approved by the FDA for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. Nivolumab has also been FDA approved to treat patients with advanced squamous non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy, as well as advanced renal cell carcinoma.
\[18F\]F-AraG is an 18F-labeled analog of arabinofuranosylguanine (AraG), a compound that has shown remarkably selective accumulation in T cells. It has several advantages over conventional \[18F\] and existing small molecule PET agents being investigated for immuno-monitoring. \[18F\]F-AraG has lower accumulation and more efficient efflux from cancer cells than a dCK agent.
Pathologic Response
Percentage of patients who experience Pathologic CR (pCR), Partial PR (pPR), or Pathologic NR (pNR) per Immune-related Pathologic Response Criteria. pCR is defined as 0% RVT (residual tumor volume) remaining in post-therapy specimen. pPR is defined a 10%\<%RVT\< 50%. pNR is defined as %RVT\>50%.
Time frame: At the time of surgery (Week 8-10)
Distant-metastasis Free Survival (DMFS)
The length of time from initiation of treatment until distant-metastasis of melanoma or death.
Time frame: Up to 5 years
Major Pathologic Response Rate (MPR)
Major Pathologic Response (MPR) is defined as %RVT≤10%.
Time frame: At the time of surgery (Week 8-10)
Relapse-Free Survival (RFS)
The length of time from initiation of treatment until melanoma relapse or death.
Time frame: Up to 24 months
6-month Relapse-Free Survival (RFS)
Percentage of patients without disease relapse at 6 months from start of treatment.
Time frame: At 6-months
12-month Relapse-Free Survival (RFS)
Percentage of patients without disease relapse at 12 months from start of treatment.
Time frame: At 12-months
24-month Relapse-Free Survival (RFS)
Percentage of patients without disease relapse at 24 months from start of treatment.
Time frame: At 24 months
Overall Survival (OS)
The length of (survival) time from the start of treatment until death from any cause.
Time frame: Up to 24 months
6-month Overall Survival (OS)
Percentage of patients alive at 6 months from the start of treatment until death from any cause.
Time frame: At 6 months
12-month Overall Survival (OS)
Percentage of patients alive at 12 months from the start of treatment until death from any cause.
Time frame: At 12-months
24-month Overall Survival (OS)
Percentage of patients alive at 24 months from the start of treatment until death from any cause.
Time frame: At 24 months
Adverse Events at Least Possibly Related to Study Treatment
Toxicities defined by NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 are adverse events classified as either possibly, probably, or definitely related to study treatment. The maximum grade for each type of toxicity will be recorded and the frequency of toxicities will be tabulated for the study population.
Time frame: Up to 47 months and 14 days
SUVmax -Tumor PET Response Via [18F]F-AraG
\[18F\]F-AraG is an experimental PET imaging agent. Tumor PET response will be assessed via standard uptake values (SUV) , SUVpeak, SUVmean, and SUVtotal.The max, peak, mean and total values for each patient will be used to determine the average standard uptake values for the study population. The possible range of SUV values is between 0 - 100. Higher SUV correlates with greater malignancy.
Time frame: At Baseline
SUVpeak -Tumor PET Response Via [18F]F-AraG
\[18F\]F-AraG is an experimental PET imaging agent. Tumor PET response will be assessed via standard uptake values (SUV), SUVpeak. The possible range of SUV values is between 0 - 100. Higher SUV correlates with greater malignancy.
Time frame: At Baseline
SUVmean -Tumor PET Response Via [18F]F-AraG
\[18F\]F-AraG is an experimental PET imaging agent. Tumor PET response will be assessed via standard uptake values (SUV), SUVmean. The possible range of SUV values is between 0 - 100. Higher SUV correlates with greater malignancy.
Time frame: At Baseline
SUVtotal -Tumor PET Response Via [18F]F-AraG
\[18F\]F-AraG is an experimental PET imaging agent. Tumor PET response will be assessed via standard uptake values (SUV), SUVtotal. The possible range of SUV values is between 0 - 100. Higher SUV correlates with greater malignancy.
Time frame: At Baseline
SUVmax -Tumor PET Response Via [18F]F-AraG
\[18F\]F-AraG is an experimental PET imaging agent. Tumor PET response will be assessed via standard uptake values (SUV) , SUVpeak, SUVmean, and SUVtotal.The max, peak, mean and total values for each patient will be used to determine the average standard uptake values for the study population. The possible range of SUV values is between 0 - 100. Higher SUV correlates with greater malignancy.
Time frame: Post Treatment - At 5 weeks
SUVpeak -Tumor PET Response Via [18F]F-AraG
\[18F\]F-AraG is an experimental PET imaging agent. Tumor PET response will be assessed via standard uptake values (SUV), SUVpeak. The possible range of SUV values is between 0 - 100. Higher SUV correlates with greater malignancy.
Time frame: Post Treatment - At 5 weeks
SUVmean -Tumor PET Response Via [18F]F-AraG
\[18F\]F-AraG is an experimental PET imaging agent. Tumor PET response will be assessed via standard uptake values (SUV), SUVmean. The possible range of SUV values is between 0 - 100. Higher SUV correlates with greater malignancy.
Time frame: Post Treatment - At 5 weeks
SUVtotal -Tumor PET Response Via [18F]F-AraG
\[18F\]F-AraG is an experimental PET imaging agent. Tumor PET response will be assessed via standard uptake values (SUV), SUVmean. The possible range of SUV values is between 0 - 100. Higher SUV correlates with greater malignancy.
Time frame: Post Treatment - At 5 weeks
Change in SUVmax -Tumor PET Response Via [18F]F-AraG
\[18F\]F-AraG is an experimental PET imaging agent. Tumor PET response will be assessed via standard uptake values (SUV) , SUVpeak, SUVmean, and SUVtotal.The max, peak, mean and total values for each patient will be used to determine the average standard uptake values for the study population. The possible range of SUV values is between 0 - 100. Higher SUV correlates with greater malignancy.
Time frame: At Baseline and Post Treatment at 5 weeks
Change in SUVpeak -Tumor PET Response Via [18F]F-AraG
\[18F\]F-AraG is an experimental PET imaging agent. Tumor PET response will be assessed via standard uptake values (SUV), SUVpeak. The possible range of SUV values is between 0 - 100. Higher SUV correlates with greater malignancy.
Time frame: Post Treatment - At 5 weeks
Change in SUVmean -Tumor PET Response Via [18F]F-AraG
\[18F\]F-AraG is an experimental PET imaging agent. Tumor PET response will be assessed via standard uptake values (SUV), SUVmean. The possible range of SUV values is between 0 - 100. Higher SUV correlates with greater malignancy.
Time frame: At Baseline and Post Treatment - At 5 weeks
Change in SUVtotal -Tumor PET Response Via [18F]F-AraG
\[18F\]F-AraG is an experimental PET imaging agent. Tumor PET response will be assessed via standard uptake values (SUV), SUVtotal. The possible range of SUV values is between 0 - 100. Higher SUV correlates with greater malignancy.
Time frame: At Baseline and Post Treatment - At 5 weeks
CD8+ T Cell Density
The quantity of CD8 + T-cells that infiltrate tumors, measured via flow cytometry.
Time frame: Pre-treatment (Screening), at Week 3 of treatment; up to 21 days
| Milestone | Nivolumab and Vidutolimod (CMP-001) Combination With [18F]F-AraG PET/CT | Nivolumab With [18F]F-AraG PET/CT |
|---|---|---|
| Started | 5 | 4 |
| Completed | 5 | 4 |
| Not completed | 0 | 0 |
Percentage of patients who experience Pathologic CR (pCR), Partial PR (pPR), or Pathologic NR (pNR) per Immune-related Pathologic Response Criteria. pCR is defined as 0% RVT (residual tumor volume) remaining in post-therapy specimen. pPR is defined a 10%\<%RVT\< 50%. pNR is defined as %RVT\>50%.
| percentage of patients | Nivolumab and Vidutolimod (CMP-001) Combination With [18F]F-AraG PET/CT | Nivolumab With [18F]F-AraG PET/CT |
|---|---|---|
| Pathologic CR | 75 (19.4 to 99.4) | 50 (6.8 to 93.2) |
| Partial PR | 25 (0.6 to 80.6) | 25 (0.6 to 80.6) |
| Pathologic NR | 0 (0 to 60.2) | 12.5 (0.6 to 80.6) |
The length of time from initiation of treatment until distant-metastasis of melanoma or death.
| Days | Nivolumab and Vidutolimod (CMP-001) Combination With [18F]F-AraG PET/CT | Nivolumab With [18F]F-AraG PET/CT |
|---|---|---|
| Distant-metastasis Free Survival (DMFS) | NA (NA to NA) | 147 (128 to NA) |
Major Pathologic Response (MPR) is defined as %RVT≤10%.
| percentage of patients | Nivolumab and Vidutolimod (CMP-001) Combination With [18F]F-AraG PET/CT | Nivolumab With [18F]F-AraG PET/CT |
|---|---|---|
| Major Pathologic Response Rate (MPR) | 75 (19.4 to 99.4) | 50 (6.8 to 93.2) |
The length of time from initiation of treatment until melanoma relapse or death.
| Days | Nivolumab and Vidutolimod (CMP-001) Combination With [18F]F-AraG PET/CT | Nivolumab With [18F]F-AraG PET/CT |
|---|---|---|
| Relapse-Free Survival (RFS) | NA (NA to NA) | 147 (128 to NA) |
Percentage of patients without disease relapse at 6 months from start of treatment.
| percentage of patients | Nivolumab and Vidutolimod (CMP-001) Combination With [18F]F-AraG PET/CT | Nivolumab With [18F]F-AraG PET/CT |
|---|---|---|
| 6-month Relapse-Free Survival (RFS) | 1.000 (1.000 to 1) | 0.333 (0.067 to 1) |
Percentage of patients without disease relapse at 12 months from start of treatment.
| percentage of patients | Nivolumab and Vidutolimod (CMP-001) Combination With [18F]F-AraG PET/CT | Nivolumab With [18F]F-AraG PET/CT |
|---|---|---|
| 12-month Relapse-Free Survival (RFS) | 1.000 (1.000 to 1) | 0.333 (0.067 to 1) |
Percentage of patients without disease relapse at 24 months from start of treatment.
| percentage of patients | Nivolumab and Vidutolimod (CMP-001) Combination With [18F]F-AraG PET/CT | Nivolumab With [18F]F-AraG PET/CT |
|---|---|---|
| 24-month Relapse-Free Survival (RFS) | 1.000 (1.000 to 1) | 0.333 (0.067 to 1) |
The length of (survival) time from the start of treatment until death from any cause.
| Days | Nivolumab and Vidutolimod (CMP-001) Combination With [18F]F-AraG PET/CT | Nivolumab With [18F]F-AraG PET/CT |
|---|---|---|
| Overall Survival (OS) | NA (NA to NA) | NA (391 to NA) |
Percentage of patients alive at 6 months from the start of treatment until death from any cause.
| percentage of patients | Nivolumab and Vidutolimod (CMP-001) Combination With [18F]F-AraG PET/CT | Nivolumab With [18F]F-AraG PET/CT |
|---|---|---|
| 6-month Overall Survival (OS) | 1.00 (1.00 to 1) | 0.75 (0.426 to 1) |
Percentage of patients alive at 12 months from the start of treatment until death from any cause.
| percentage of patients | Nivolumab and Vidutolimod (CMP-001) Combination With [18F]F-AraG PET/CT | Nivolumab With [18F]F-AraG PET/CT |
|---|---|---|
| 12-month Overall Survival (OS) | 1.00 (1.00 to 1) | 0.75 (0.426 to 1) |
Percentage of patients alive at 24 months from the start of treatment until death from any cause.
| percentage of patients | Nivolumab and Vidutolimod (CMP-001) Combination With [18F]F-AraG PET/CT | Nivolumab With [18F]F-AraG PET/CT |
|---|---|---|
| 24-month Overall Survival (OS) | 1.00 (1.00 to 1) | 0.75 (0.426 to 1) |
Toxicities defined by NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 are adverse events classified as either possibly, probably, or definitely related to study treatment. The maximum grade for each type of toxicity will be recorded and the frequency of toxicities will be tabulated for the study population.
| Participants | Nivolumab and Vidutolimod (CMP-001) Combination With [18F]F-AraG PET/CT | Nivolumab With [18F]F-AraG PET/CT |
|---|---|---|
| Anemia | 1 | 0 |
| Adrenal insufficiency | 0 | 1 |
| Hypothyroidism | 1 | 0 |
| Diarrhea | 1 | 1 |
| Nausea | 1 | 0 |
| Chills | 4 | 0 |
| Fatigue | 4 | 0 |
| Fever | 2 | 0 |
| Neck edema | 3 | 0 |
| Pain | 2 | 0 |
| Aspartate aminotransferase increased | 0 | 0 |
| Blood bilirubin increased | 1 | 1 |
| Blood lactate dehydrogenase increased | 0 | 0 |
| Blood urea nitrogen increased | 0 | 1 |
| Neutrophil count decreased | 1 | 0 |
| Thyroid stimulating hormone increased | 0 | 1 |
| Hyponatremia | 3 | 1 |
| Hypophosphatemia | 0 | 1 |
| Arthralgia | 1 | 0 |
| Back pain | 1 | 0 |
| Generalized muscle weakness | 1 | 0 |
| Headache | 2 | 0 |
| Nasal congestion | 1 | 0 |
| Pruritus | 0 | 2 |
| Rash acneiform | 3 | 0 |
| Rash maculo-papular | 0 | 1 |
| Skin hypopigmentation | 0 | 1 |
| Flushing | 1 | 0 |
| Hypertension | 2 | 0 |
\[18F\]F-AraG is an experimental PET imaging agent. Tumor PET response will be assessed via standard uptake values (SUV) , SUVpeak, SUVmean, and SUVtotal.The max, peak, mean and total values for each patient will be used to determine the average standard uptake values for the study population. The possible range of SUV values is between 0 - 100. Higher SUV correlates with greater malignancy.
| g/ml | Nivolumab and Vidutolimod (CMP-001) Combination With [18F]F-AraG PET/CT | Nivolumab With [18F]F-AraG PET/CT |
|---|---|---|
| SUVmax -Tumor PET Response Via [18F]F-AraG | 3.37 ± 1.10 | 3.27 ± 1.12 |
\[18F\]F-AraG is an experimental PET imaging agent. Tumor PET response will be assessed via standard uptake values (SUV), SUVpeak. The possible range of SUV values is between 0 - 100. Higher SUV correlates with greater malignancy.
| g/ml | Nivolumab and Vidutolimod (CMP-001) Combination With [18F]F-AraG PET/CT | Nivolumab With [18F]F-AraG PET/CT |
|---|---|---|
| SUVpeak -Tumor PET Response Via [18F]F-AraG | 2.29 ± 1.04 | 2.69 ± 1.70 |
\[18F\]F-AraG is an experimental PET imaging agent. Tumor PET response will be assessed via standard uptake values (SUV), SUVmean. The possible range of SUV values is between 0 - 100. Higher SUV correlates with greater malignancy.
| g/ml | Nivolumab and Vidutolimod (CMP-001) Combination With [18F]F-AraG PET/CT | Nivolumab With [18F]F-AraG PET/CT |
|---|---|---|
| SUVmean -Tumor PET Response Via [18F]F-AraG | 0.905 ± 0.428 | 0.895 ± 0.372 |
\[18F\]F-AraG is an experimental PET imaging agent. Tumor PET response will be assessed via standard uptake values (SUV), SUVtotal. The possible range of SUV values is between 0 - 100. Higher SUV correlates with greater malignancy.
| g/ml | Nivolumab and Vidutolimod (CMP-001) Combination With [18F]F-AraG PET/CT | Nivolumab With [18F]F-AraG PET/CT |
|---|---|---|
| SUVtotal -Tumor PET Response Via [18F]F-AraG | 21.7 ± 11.7 | 40.6 ± 30.1 |
\[18F\]F-AraG is an experimental PET imaging agent. Tumor PET response will be assessed via standard uptake values (SUV) , SUVpeak, SUVmean, and SUVtotal.The max, peak, mean and total values for each patient will be used to determine the average standard uptake values for the study population. The possible range of SUV values is between 0 - 100. Higher SUV correlates with greater malignancy.
| g/ml | Nivolumab and Vidutolimod (CMP-001) Combination With [18F]F-AraG PET/CT | Nivolumab With [18F]F-AraG PET/CT |
|---|---|---|
| SUVmax -Tumor PET Response Via [18F]F-AraG | 2.92 ± 1.15 | 2.90 ± 0.311 |
\[18F\]F-AraG is an experimental PET imaging agent. Tumor PET response will be assessed via standard uptake values (SUV), SUVpeak. The possible range of SUV values is between 0 - 100. Higher SUV correlates with greater malignancy.
| g/ml | Nivolumab and Vidutolimod (CMP-001) Combination With [18F]F-AraG PET/CT | Nivolumab With [18F]F-AraG PET/CT |
|---|---|---|
| SUVpeak -Tumor PET Response Via [18F]F-AraG | 1.64 ± 0.891 | 1.55 ± 0.339 |
\[18F\]F-AraG is an experimental PET imaging agent. Tumor PET response will be assessed via standard uptake values (SUV), SUVmean. The possible range of SUV values is between 0 - 100. Higher SUV correlates with greater malignancy.
| g/ml | Nivolumab and Vidutolimod (CMP-001) Combination With [18F]F-AraG PET/CT | Nivolumab With [18F]F-AraG PET/CT |
|---|---|---|
| SUVmean -Tumor PET Response Via [18F]F-AraG | 0.761 ± 0.453 | 0.890 ± 0.403 |
\[18F\]F-AraG is an experimental PET imaging agent. Tumor PET response will be assessed via standard uptake values (SUV), SUVmean. The possible range of SUV values is between 0 - 100. Higher SUV correlates with greater malignancy.
| g/ml | Nivolumab and Vidutolimod (CMP-001) Combination With [18F]F-AraG PET/CT | Nivolumab With [18F]F-AraG PET/CT |
|---|---|---|
| SUVtotal -Tumor PET Response Via [18F]F-AraG | 14.9 ± 1.82 | 15.7 ± 0.863 |
\[18F\]F-AraG is an experimental PET imaging agent. Tumor PET response will be assessed via standard uptake values (SUV) , SUVpeak, SUVmean, and SUVtotal.The max, peak, mean and total values for each patient will be used to determine the average standard uptake values for the study population. The possible range of SUV values is between 0 - 100. Higher SUV correlates with greater malignancy.
| g/ml | Nivolumab and Vidutolimod (CMP-001) Combination With [18F]F-AraG PET/CT | Nivolumab With [18F]F-AraG PET/CT |
|---|---|---|
| Change in SUVmax -Tumor PET Response Via [18F]F-AraG | -0.498 ± 0.283 | 0.183 ± 0.462 |
\[18F\]F-AraG is an experimental PET imaging agent. Tumor PET response will be assessed via standard uptake values (SUV), SUVpeak. The possible range of SUV values is between 0 - 100. Higher SUV correlates with greater malignancy.
| g/ml | Nivolumab and Vidutolimod (CMP-001) Combination With [18F]F-AraG PET/CT | Nivolumab With [18F]F-AraG PET/CT |
|---|---|---|
| Change in SUVpeak -Tumor PET Response Via [18F]F-AraG | -0.822 ± 0.655 | -0.215 ± 0.460 |
\[18F\]F-AraG is an experimental PET imaging agent. Tumor PET response will be assessed via standard uptake values (SUV), SUVmean. The possible range of SUV values is between 0 - 100. Higher SUV correlates with greater malignancy.
| g/ml | Nivolumab and Vidutolimod (CMP-001) Combination With [18F]F-AraG PET/CT | Nivolumab With [18F]F-AraG PET/CT |
|---|---|---|
| Change in SUVmean -Tumor PET Response Via [18F]F-AraG | -0.170 ± 0.122 | 0.153 ± 0.252 |
\[18F\]F-AraG is an experimental PET imaging agent. Tumor PET response will be assessed via standard uptake values (SUV), SUVtotal. The possible range of SUV values is between 0 - 100. Higher SUV correlates with greater malignancy.
| g/ml | Nivolumab and Vidutolimod (CMP-001) Combination With [18F]F-AraG PET/CT | Nivolumab With [18F]F-AraG PET/CT |
|---|---|---|
| Change in SUVtotal -Tumor PET Response Via [18F]F-AraG | -11.2 ± 10.6 | -8.91 ± 15.7 |
The quantity of CD8 + T-cells that infiltrate tumors, measured via flow cytometry.
Results for this outcome have not been posted.
Collected over Adverse Events data were collected for up to 13 months. All-Cause Mortality data was collected for up to 47 months and 14 days.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Nivolumab and Vidutolimod (CMP-001) Combination With [18F]F-AraG PET/CT | 0/5 (0%) | 0/5 (0%) | 5/5 (100%) |
| Nivolumab With [18F]F-AraG PET/CT | 1/4 (25%) | 0/4 (0%) | 4/4 (100%) |
| Event | Nivolumab and Vidutolimod (CMP-001) Combination With [18F]F-AraG PET/CT | Nivolumab With [18F]F-AraG PET/CT |
|---|---|---|
| ChillsGENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | 4/5 | 0/4 |
| FatigueGENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | 4/5 | 1/4 |
| PainGENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | 4/5 | 1/4 |
| AnemiaBLOOD AND LYMPHATIC SYSTEM DISORDERS | 2/5 | 3/4 |
| Neck edemaGENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | 3/5 | 0/4 |
| Blood lactate dehydrogenase increasedINVESTIGATIONS | 3/5 | 2/4 |
| HyponatremiaMETABOLISM AND NUTRITION DISORDERS | 3/5 | 2/4 |
| Rash acneiformSKIN AND SUBCUTANEOUS TISSUE DISORDERS | 3/5 | 0/4 |
| DiarrheaGASTROINTESTINAL DISORDERS | 1/5 | 2/4 |
| Blood bilirubin increasedINVESTIGATIONS | 0/5 | 2/4 |
All enrolled participants.
| Age, Continuous(years) | Nivolumab and Vidutolimod (CMP-001) Combination With [18F]F-AraG PET/CT | Nivolumab With [18F]F-AraG PET/CT | Total |
|---|---|---|---|
| Mean | 69.0 ± 11.9 | 74.8 ± 2.63 | 71.6 ± 9.08 |
| Sex: Female, Male(Participants) | Nivolumab and Vidutolimod (CMP-001) Combination With [18F]F-AraG PET/CT | Nivolumab With [18F]F-AraG PET/CT | Total |
|---|---|---|---|
| Female | 2 | 1 | 3 |
| Male | 3 | 3 | 6 |
| Ethnicity (NIH/OMB)(Participants) | Nivolumab and Vidutolimod (CMP-001) Combination With [18F]F-AraG PET/CT | Nivolumab With [18F]F-AraG PET/CT | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 5 | 4 | 9 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Nivolumab and Vidutolimod (CMP-001) Combination With [18F]F-AraG PET/CT | Nivolumab With [18F]F-AraG PET/CT | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 5 | 4 | 9 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2020 to primary completion in Aug 2024, 47 months.
Results were first posted in Jul 2026, 1 year 10 months after primary completion.
Of 277 non-industry phase 2 interventional studies under Melanoma, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 94. This study's 47 months is below that.
Counting every sponsor, half of 383 studies reached it within 53 months; a quarter within 32 and three quarters within 88.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nivolumab
Diwakar Davar